These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10471591)

  • 21. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.
    Liao S; Palmer M; Fowler C; Nayak RK
    J Clin Pharmacol; 1996 Nov; 36(11):1072-7. PubMed ID: 8973996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
    Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora.
    Edlund C; Sjöstedt S; Nord CE
    Scand J Infect Dis; 1997; 29(4):383-6. PubMed ID: 9360254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients.
    Traunmüller F; Thalhammer-Scherrer R; Locker GJ; Losert H; Schmid R; Staudinger T; Thalhammer F
    J Antimicrob Chemother; 2001 Feb; 47(2):229-31. PubMed ID: 11157914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.
    Rodvold KA; Danziger LH; Gotfried MH
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2450-7. PubMed ID: 12878504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers.
    Guay DR; Opsahl JA; McMahon FG; Vargas R; Matzke GR; Flor S
    Antimicrob Agents Chemother; 1992 Feb; 36(2):308-12. PubMed ID: 1605596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.
    Furlanut M; Brollo L; Lugatti E; Di Qual E; Dolcet F; Talmassons G; Pea F
    J Antimicrob Chemother; 2003 Jan; 51(1):101-6. PubMed ID: 12493793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Data from a randomised, 2 x 2 crossover trial in healthy volunteers.
    Almeida S; Filipe A; Almeida A; Wong H; Caparrós N; Tanguay M
    Arzneimittelforschung; 2005; 55(7):414-9. PubMed ID: 16080281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs.
    Yabe K; Murakami Y; Nishida S; Sekiguchi M; Furuham K; Goryo M; Okada K
    J Vet Med Sci; 2001 Aug; 63(8):867-72. PubMed ID: 11558541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients.
    Lichtenstein SJ; Rinehart M;
    J AAPOS; 2003 Oct; 7(5):317-24. PubMed ID: 14566313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of levofloxacin in healthy Thai male volunteers.
    Chulavatnatol S; Chindavijak B; Vibhagool A; Wananukul W; Sriapha C; Sirisangtragul C
    J Med Assoc Thai; 1999 Nov; 82(11):1127-35. PubMed ID: 10659548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
    Timmers GJ; Dijstelbloem Y; Simoons-Smit AM; van Winkelhoff AJ; Touw DJ; Vandenbroucke-Grauls CM; Huijgens PC
    Bone Marrow Transplant; 2004 Apr; 33(8):847-53. PubMed ID: 14755314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.
    Sowinski KM; Lucksiri A; Kays MB; Scott MK; Mueller BA; Hamburger RJ
    Am J Kidney Dis; 2003 Aug; 42(2):342-9. PubMed ID: 12900817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of single rising doses of ofloxacin in healthy volunteers.
    Marchbanks CR; Dudley MN; Flor S; Beals B
    Pharmacotherapy; 1992; 12(1):45-9. PubMed ID: 1549538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects.
    Zhang L; Li JT; Lu Y; Li MN; Zhang YL; Liu Y; Li TY; Zhang JW
    Acta Pharmacol Sin; 2002 Apr; 23(4):381-4. PubMed ID: 11931699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Sethi S; Fogarty C; Fulambarker A
    Respir Med; 2004 Aug; 98(8):697-707. PubMed ID: 15303633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.
    Hansen E; Bucher M; Jakob W; Lemberger P; Kees F
    Intensive Care Med; 2001 Feb; 27(2):371-5. PubMed ID: 11396281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.